Juvenile Fibromyalgia in Patients with Juvenile Idiopathic Arthritis: Utility of the Pain and Symptom Assessment Tool (PSAT)

2021 ◽  
Author(s):  
Melissa S Tesher ◽  
Thomas B Graham ◽  
Tracy Ting ◽  
Susmita Kashikar‐Zuck ◽  
Niccola Lynch ◽  
...  
Keyword(s):  
Juvenile Idiopathic Arthritis ◽  
Assessment Tool ◽  
Symptom Assessment ◽  
Juvenile Fibromyalgia

Multi-Dimensional Gastrointestinal Symptom Severity Index: Validation of a Brief GI Symptom Assessment Tool

2015 ◽  
Vol 60 (8) ◽  
pp. 2270-2279 ◽  
Author(s):  
Michael D. Crowell ◽  
Sarah B. Umar ◽  
Brian E. Lacy ◽  
Michael P. Jones ◽  
John K. DiBaise ◽  
...  
Keyword(s):  
Symptom Severity ◽  
Gastrointestinal Symptom ◽  
Assessment Tool ◽  
Symptom Assessment ◽  
Severity Index

Symptom assessment tool for overactive bladder syndrome—overactive bladder symptom score

Urology ◽  
2006 ◽  
Vol 68 (2) ◽  
pp. 318-323 ◽  
Author(s):  
Yukio Homma ◽  
Masaki Yoshida ◽  
Narihito Seki ◽  
Osamu Yokoyama ◽  
Hidehiro Kakizaki ◽  
...  
Keyword(s):  
Overactive Bladder ◽  
Symptom Score ◽  
Assessment Tool ◽  
Symptom Assessment ◽  
Overactive Bladder Syndrome ◽  
Bladder Symptom ◽  
Overactive Bladder Symptom Score

The Edmonton Symptom Assessment System: A narrative review of a standardized symptom assessment tool in head and neck oncology

Oral Oncology ◽  
2021 ◽  
Vol 123 ◽  
pp. 105595
Author(s):  
Christopher W. Noel ◽  
David Forner ◽  
Douglas B. Chepeha ◽  
Elif Baran ◽  
Kelvin K.W. Chan ◽  
...  
Keyword(s):  
Head And Neck ◽  
Assessment Tool ◽  
Symptom Assessment ◽  
Narrative Review ◽  
Assessment System ◽  
Head And Neck Oncology ◽  
Edmonton Symptom Assessment System ◽  
System A

Evaluation of a Novel, Icon-Based Symptom Assessment Tool for Gastroenterology

2015 ◽  
Vol 110 ◽  
pp. S754-S755
Author(s):  
Lucy Lu ◽  
Richard H. Hunt ◽  
David Armstrong
Keyword(s):  
Assessment Tool ◽  
Symptom Assessment

Impact of a cancer management program.

2012 ◽  
Vol 30 (34_suppl) ◽  
pp. 227-227 ◽  
Author(s):  
J. Russell Hoverman ◽  
Ira Klein ◽  
Deb Harrison ◽  
Jad Hayes ◽  
Jody S. Garey ◽  
...  
Keyword(s):  
Assessment Tool ◽  
Symptom Assessment ◽  
Management Program ◽  
Preliminary Evaluation ◽  
Quality Initiatives ◽  
Cancer Management ◽  
Report Quality ◽  
Advance Care ◽  
Pre Treatment ◽  
Chemotherapy Patients

227 Background: US Oncology, Inc., Texas Oncology (TxO) and Aetna are engaged in a pilot program, Innovent Oncology (IOP) to evaluate clinical and financial impacts of Pathways (PW), a nursing call intervention for chemotherapy patients (pt support services-PSS), and an advance care planning (ACP) initiative. We report quality initiatives, PW compliance and ACP, from the program at 18 months, and IP and ER admits at 12 months. Methods: Eligible Aetna pts with PW diagnoses, treated by TxO were enrolled. PW compliance was tracked. PSS calls occurred at regular intervals during chemotherapy. Symptoms, quality of life, and depression were screened each call with referrals to TxO as needed for management. ACP was initiated in month 2 of IOP. To support IOP, a leadership team comprising physicians, pharmacists and nurses was established. IP,ER data on predefined subgroups were compared to diagnosis-adjusted rates from the baseline prior year. Results: The program enrolled 184 patients from June 1, 2010 – Decembe 30, 2011 with 278 regimens ordered. Pathway adherence improved from 67% to 75%. 81% enrolled in PSS; of these, 83% were introduced to ACP, with 11% (n=16) completing a full ACP discussion. PSS made 906 calls to pts and assessed pain at 80% of contacts. IP, ER utilization rates after 12 months of IOP are reported (see Table). Conclusions: This is a preliminary evaluation with small numbers. Results suggest cancer patients can be identified pre-treatment; a proactive nurse call system is feasible and well received; a symptom assessment tool can be systematically implemented, communication on ACP initiated; and a pathways program enhanced. A reduction of ER visits by 39.8%, IP admits by 16.5 %, and inpatient days/member by 35.9% are very promising trends. A bootstrap shows 97% of scenarios with IP utilization reduction, and 96% with ER utilization reduction. [Table: see text]

scholarly journals Patient-Reported Outcome Measure for Real-time Symptom Assessment in Women With Endometriosis: Focus Group Study (Preprint)

2021 ◽  
Author(s):  
Esther van Barneveld ◽  
Arianne Lim ◽  
Nehalennia van Hanegem ◽  
Lisa Vork ◽  
Alexandra Herrewegh ◽  
...  
Keyword(s):  
Assessment Tool ◽  
Contextual Information ◽  
Treatment Plan ◽  
Compliance Rate ◽  
Symptom Assessment ◽  
Personalized Treatment ◽  
Focus Group Study ◽  
Digital Tool ◽  
Patient Reported ◽  
Momentary Assessment

BACKGROUND Symptoms related to endometriosis have a significant impact on the quality of life, and symptoms often recur. The experience sampling method (ESM), a digital questioning method characterized by randomly repeated momentary assessments, has several advantages over traditionally used measurements, including the ability to assess the temporal relationship between variables such as physical, mental, and social factors. OBJECTIVE The aim of this study is to develop an ESM tool for patients with endometriosis to accurately measure symptoms and their course over time, allowing for personalized treatment and adequate monitoring of treatment efficacy in individual patients. METHODS On the basis of international guidelines, items from validated questionnaires were selected through a literature review and during focus groups and multidisciplinary expert meetings. Data analysis was conducted using ATLAS.ti (ATLAS.ti Scientific Software Development GmbH). The feasibility and usability of the newly developed momentary assessment tool were tested for 28 consecutive days in 5 patients with endometriosis-related pain symptoms. RESULTS Momentary assessment items contained questions concerning endometriosis symptoms, general somatic symptoms, psychological symptoms, contextual information, and the use of food and medication. A morning questionnaire on sleep and sexuality was included. In a pilot study, the patients considered the tool easy to use but time consuming. The average compliance rate of momentary assessments was 37.8% (106/280), with the highest completion rate during the first week (39/70, 56%). Therefore, it is advisable to use the ESM for a maximum of 7 days. CONCLUSIONS A new digital tool for endometriosis symptom assessment was developed using the ESM, which may help overcome the limitations of current retrospective questionnaires. After validation and testing, future studies will be planned to evaluate the use of this tool in a clinical setting in order to propose a personalized treatment plan for women with endometriosis. CLINICALTRIAL

The use of a palliative care tool in a community private practice.

2012 ◽  
Vol 30 (34_suppl) ◽  
pp. 95-95
Author(s):  
Tallat Mahmood ◽  
Helen Shock ◽  
Jane Severson ◽  
Douglas W. Blayney ◽  
Keyword(s):  
Palliative Care ◽  
Assessment Tool ◽  
Symptom Burden ◽  
Symptom Assessment ◽  
Target Population ◽  
Ease Of Use ◽  
Assessment System ◽  
Individual Patient Level ◽  
Oncology Practice ◽  
The Individual

95 Background: Although symptom assessment is a routine part of oncology care, data from the Michigan Oncology Quality Consortium (MOQC) showed variation in individual practice (Health Affairs 31:718, 2012). As part of the MOQC Palliative Care Demonstration Project, we implemented the Edmonton Symptom Assessment System(ESAS) in a private oncology clinic. ESAS is a valid and reliable assessment tool that evaluates nine common symptoms experienced by cancer patients. Our target population was patients with active cancer undergoing chemotherapy. Methods: Initial implementation focused on patients of only one of the practice’s physicians. Symptoms rated >3 were considered symptomatic and were addressed by the physician. To monitor overall performance, a practice profile was compiled from the individual ESAS results. For symptoms with the greatest severity and incidence, targeted resources were developed and integrated in new electronic medical record templates and educational sessions with patients. Results: Managing change incrementally with weekly reassessment of implementation problems was effective. Use of the ESAS tool allowed for a focused discussion of the patient symptomatology and lead to better efficiency for the physician. Understanding the symptom burden of the patient population and implementing practice wide interventions helped to reduce the symptom burden at an individual patient level. Conclusions: The ease of use of the ESAS tool makes it highly successful in the private oncology practice setting. Profiling the symptom burden at a practice level facilitates targeted improvements and monitoring of performance over time. [Table: see text]

Psychosocial Risk, Symptom Burden, and Concerns in Families Affected by Childhood Cancer

2021 ◽  
Author(s):  
K. Brooke Russell ◽  
Michaela Patton ◽  
Courtney Tromburg ◽  
Hailey Zwicker ◽  
Gregory M. T. Guilcher ◽  
...  
Keyword(s):  
Assessment Tool ◽  
Psychosocial Support ◽  
Symptom Burden ◽  
Symptom Assessment ◽  
Assessment System ◽  
Psychosocial Risk ◽  
Psychosocial Assessment ◽  
Future Research ◽  
Risk Category ◽  
Risk Symptom

Abstract PURPOSE: The revised Psychosocial Assessment Tool (PATrev) is a common family-level risk-based screening tool for pediatric oncology that has gained support for its ability to predict, at diagnosis, the degree of psychosocial support a family may require throughout the treatment trajectory. However, ongoing screening for symptoms and concerns (e.g., feeling alone, understanding treatment) remain underutilized. Resource limitations necessitate triaging and intervention based on need and risk. Given the widespread use of the PATrev, we sought to explore the association between family psychosocial risk, symptom burden (as measured by the revised Edmonton Symptom Assessment System; ESAS-r), and concerns (as measured by the Canadian Problem Checklist; CPC). METHODS: Families (n = 85) with children between 2–18 years of age (M = 11.98, male: 62.4%) on or off treatment for cancer were recruited from the Alberta Children’s Hospital. One parent from each family completed the PATrev and the CPC. Participants 8–18 years of age completed the ESAS-r. RESULTS: Risk category (unviersal/low risk = 67.1%, targeted/intermediate risk = 21.1%, clinical/high risk = 5.9%), predicted symptom burden (F[2, 63.07] = 4.57, p = .014) and concerns (F[2, 80.08] = 16.34, p < .001), such that universal risk was associated with significantly lower symptom burden and fewer concerns. CONCLUSION: Family psychosocial risk is associated with cross-sectionally identified concerns and symptom burden, suggesting that resources might be prioritized for families with the greatest predicted need. Future research should evaluate the predictive validity of the PATrev to identify longitudinal concerns and symptom burden throughout the cancer trajectory.

Sign in / Sign up

Export Citation Format

Share Document